Table 3.
Comparison of FFBL conspicuity on PET/MRI versus PET/CT: quantitative analysis
| Imaging parameter | PET/MRI (mean ± SD) | PET/CT (mean ± SD) | p-value | PET/MRI (as % of PET/CT) |
|---|---|---|---|---|
| BB SUV-max | 1.9 ± 1.0 | 2.2 ± 0.9 | 0.002* | −14.2 %* |
| BB SUV-mean | 1.1 ± 0.6 | 1.4 ± 0.5 | <0.001* | −20.5 %* |
| BB Volume | 3.9 ± 4.2 | 3.8 ± 4.8 | 0.735 | +2.6 % |
| NL SUV-max | 2.4 ± 0.5 | 3.1 ± 0.6 | <0.001* | −23.4 %* |
| NL SUV-mean | 1.8 ± 0.3 | 2.5 ± 0.5 | <0.001* | −27.6 %* |
| FFBL SUV-max | 7.0 ± 4.0 | 7.5 ± 3.8 | 0.068 | −6.2 % |
| FFBL SUV-mean | 4.0 ± 2.0 | 4.3 ± 1.8 | 0.009* | −6.5 %* |
| FFBL TG (SUV*ml) | 31.4 ± 35.5 | 33.6 ± 41.3 | 0.469 | −6.4 % |
| FFBL Volume (ml) | 9.4 ± 12.2 | 9.7 ± 13.1 | 0.757 | −2.2 % |
| FFBL 40 %-iso SUV-mean | 4.5 ± 2.5 | 4.8 ± 2.3 | 0.013* | −7.0 %* |
| FFBL 50 %-iso SUV-mean | 4.9 ± 2.8 | 5.2 ± 2.7 | 0.028* | −6.3 %* |
| FFBL 60 %-iso SUV-mean | 5.4 ± 3.2 | 5.7 ± 3.0 | 0.056 | −6.1 % |
| [FFBL SUV-max]/ | 4.2 ± 2.7 | 3.7 ± 2.0 | 0.332 | +12.4 % |
| [BB SUV-mean] | ||||
| [FFBL SUV-mean]/ | 4.4 ± 2.7 | 3.4 ± 1.9 | <0.001* | +26.7 %* |
| [BB SUV-mean] | ||||
| [FFBL 40 %-iso SUV-mean]/ | 4.9 ± 3.1 | 3.9 ± 2.2 | <0.001* | +26.1 %* |
| [BB SUV-mean] | ||||
| [FFBL 50 %-iso SUV-mean]/ | 5.3 ± 3.4 | 4.2 ± 2.4 | <0.001* | +26.6 %* |
| [BB SUV-mean] | ||||
| [FFBL 60 %-iso SUV-mean]/ | 5.7 ± 3.7 | 4.6 ± 2.6 | 0.001* | +26.6 %* |
| [BB SUV-mean] |
*statistically significant results (p < 0.05)
Abbreviations: FFBL – FDG-avid focal bone lesion; BB – background bone; NL – normal liver; SUV – standardized uptake value; iso – isocontour; TG – total glycolysis; SD – standard deviation